{"filing":{"accession_number":"0001104659-26-073419","cik":"0001875558","ticker":"NVCT","company_name":"Nuvectis Pharma, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"tm2617533d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926073419/tm2617533d1_8k.htm"},"events":[{"id":10754,"run_id":9435,"accession_number":"0001104659-26-073419","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This Item 5.07 discloses the results of Nuvectis Pharma's 2026 Annual Meeting held on June 11, 2026, including voting outcomes for the election of a Class I director (Ron Bentsur) and ratification of Kesselman \u0026 Kesselman as independent auditor. All proposals were approved. While the filing notes a minor correction to the share count in the proxy statement (27.7M stated vs. 26.6M actual), this does not affect vote validity or outcomes. The core disclosure is the shareholder vote results, which is material to investors as it confirms board composition and auditor selection.","company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7148,"accession_number":"0001104659-26-073419","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of Nuvectis Pharma's 2026 Annual Meeting held on June 11, 2026, including voting outcomes for the election of a Class I director (Ron Bentsur) and ratification of Kesselman \u0026 Kesselman as independent auditor. All proposals were approved. While the filing notes a minor correction to the share count in the proxy statement (27.7M stated vs. 26.6M actual), this does not affect vote validity or outcomes. The core disclosure is the shareholder vote results, which is material to investors as it confirms board composition and auditor selection.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:15:50.815986+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7148,"accession_number":"0001104659-26-073419","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of Nuvectis Pharma's 2026 Annual Meeting held on June 11, 2026, including voting outcomes for the election of a Class I director (Ron Bentsur) and ratification of Kesselman \u0026 Kesselman as independent auditor. All proposals were approved. While the filing notes a minor correction to the share count in the proxy statement (27.7M stated vs. 26.6M actual), this does not affect vote validity or outcomes. The core disclosure is the shareholder vote results, which is material to investors as it confirms board composition and auditor selection.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:15:50.815986+00:00","company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","filing_date":"2026-06-12"}]}